Market capitalization | $4.82m |
Enterprise Value | $7.47m |
PER (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 4.39 |
P/S ratio (TTM) P/S ratio | 2.84 |
P/B ratio (TTM) P/B ratio | 0.23 |
Sales growth (TTM) Sales growth | -21.24% |
Turnover (TTM) Turnover | $1.70m |
EBIT (operating result TTM) EBIT | $-13.95m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
Jun '23 |
+/-
%
|
||
Net profit | -4.42 -4.42 |
13%
13%
|
|
Depreciation and amortization | - - |
-
|
|
Share compensation | - - |
-
|
|
Operating cash flow | - - |
-
|
|
Investments | - - |
-
|
|
Dividend paid | - - |
-
|
|
Free cash flow | - - |
-
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.
Head office | Virgin Islands, British |
CEO | Hao Yu |
Employees | 75 |
Founded | 2010 |
Website | www.anpacbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.